711 related articles for article (PubMed ID: 9440663)
21. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols.
Gable CB; Tierce JC; Simison D; Ward D; Motte K
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):413-20. PubMed ID: 8673552
[TBL] [Abstract][Full Text] [Related]
22. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients.
Scharfstein JA; Paltiel AD; Freedberg KA
Med Decis Making; 1997; 17(4):373-81. PubMed ID: 9343795
[TBL] [Abstract][Full Text] [Related]
24. Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.
Cheever LW; Chaisson RE; Gallant JE
West J Med; 1996; 165(1-2):67-73. PubMed ID: 8855697
[No Abstract] [Full Text] [Related]
25. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
26. PHS guidelines map out prevention routes through terrain of infections. Public Health Service.
AIDS Alert; 1995 Sep; 10(9):109-11. PubMed ID: 11362773
[TBL] [Abstract][Full Text] [Related]
27. Prophylaxis of opportunistic infections in HIV/AIDS.
Goldschmidt RH
Am Fam Physician; 1997 Sep; 56(4):1039-40. PubMed ID: 9310055
[No Abstract] [Full Text] [Related]
28. HIV: prevention of opportunistic infections.
Ioannidis J; Wilkinson D
Clin Evid; 2005 Jun; (13):834-53. PubMed ID: 16135281
[No Abstract] [Full Text] [Related]
29. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States.
Asch SM; Gifford AL; Bozzette SA; Turner B; Mathews WC; Kuromiya K; Cunningham W; Andersen R; Shapiro M; Rastegar A; McCutchan JA
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):340-4. PubMed ID: 11707670
[TBL] [Abstract][Full Text] [Related]
30. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
Rose DN; Sacks HS
AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
[TBL] [Abstract][Full Text] [Related]
32. Stopping preventive treatments.
Fornataro K; Jefferys R
Body Posit; 1999 Jul; 12(7):9-10. PubMed ID: 11367080
[TBL] [Abstract][Full Text] [Related]
33. Current status of prophylaxis for opportunistic infections in HIV-infected patients.
Decker CF; Masur H
AIDS; 1994 Jan; 8(1):11-20. PubMed ID: 8011221
[No Abstract] [Full Text] [Related]
34. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
35. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
[TBL] [Abstract][Full Text] [Related]
36. The lifetime cost of current human immunodeficiency virus care in the United States.
Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
[TBL] [Abstract][Full Text] [Related]
37. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.
Freedberg KA; Tosteson AN; Cohen CJ; Cotton DJ
J Acquir Immune Defic Syndr (1988); 1991; 4(5):521-31. PubMed ID: 1673157
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis for opportunistic infections in patients with HIV infection.
Gallant JE; Moore RD; Chaisson RE
Ann Intern Med; 1994 Jun; 120(11):932-44. PubMed ID: 8172439
[TBL] [Abstract][Full Text] [Related]
39. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda.
Pitter C; Kahn JG; Marseille E; Lule JR; McFarland DA; Ekwaru JP; Bunnell R; Coutinho A; Mermin J
J Acquir Immune Defic Syndr; 2007 Mar; 44(3):336-43. PubMed ID: 17327758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
